Evexia Lifecare

  • Market Cap: Micro Cap
  • Industry: Edible Oil
  • ISIN: INE313M01030
  • NSEID:
  • BSEID: 524444
INR
1.63
0.01 (0.62%)
BSENSE

Feb 03

BSE+NSE Vol: 19.49 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

19.49 lacs (-60.93%) Volume

Shareholding (Dec 2025)

FII

0.47%

Held by 1 FIIs

DII

0.07%

Held by 1 DIIs

Promoter

3.49%

how big is Evexia Lifecare?

06-Jun-2025

As of Jun 06, Evexia Lifecare Ltd has a market capitalization of 469.33 Cr, classifying it as a Micro Cap company, with net sales of 93.25 Cr and a net profit of 1.36 Cr for the latest four quarters. The shareholder's funds are valued at 129.40 Cr, and total assets amount to 883.00 Cr as of Mar'24.

Market Cap: As of Jun 06, Evexia Lifecare Ltd has a market capitalization of 469.33 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Evexia Lifecare Ltd reported net sales of 93.25 Cr and a net profit of 1.36 Cr. This data is consolidated.<BR><BR>Balance Sheet Snapshot: This is consolidated data for the latest annual period ending in Mar'24. The shareholder's funds are valued at 129.40 Cr, and the total assets amount to 883.00 Cr.

View full answer

Who are in the management team of Evexia Lifecare?

06-Jun-2025

As of March 2022, the management team of Evexia Lifecare includes Jayesh R Thakkar (Chairman & Managing Director), Kartik Mistry, Chandresh Kumar Vishnubhai Kahar, Hasmukhbhai Thakkar, Naresh Arvindbhai Patel, Payal Gajjar (all Independent Directors), Parul Samalia (Company Secretary & Compliance Officer), and Parth Patel (Additional Director). They oversee the company's operations and governance.

As of March 2022, the management team of Evexia Lifecare includes the following individuals:<BR><BR>1. Jayesh R Thakkar - Chairman & Managing Director<BR>2. Kartik Mistry - Independent Director<BR>3. Chandresh Kumar Vishnubhai Kahar - Independent Director<BR>4. Hasmukhbhai Thakkar - Independent Director<BR>5. Naresh Arvindbhai Patel - Independent Director<BR>6. Payal Gajjar - Independent Director<BR>7. Parul Samalia - Company Secretary & Compliance Officer<BR>8. Parth Patel - Additional Director<BR><BR>This team is responsible for overseeing the company's operations and governance.

View full answer

What does Evexia Lifecare do?

06-Jun-2025

Evexia Lifecare Ltd operates in the edible oil industry as a micro-cap company, with a market cap of Rs 469 Cr and reported net sales of 24 Cr and net profit of 0 Cr for the quarter ending March 2025. The company was renamed from Jal Hi Power Petrochem Limited in December 2020.

Overview:<BR>Evexia Lifecare Ltd operates in the edible oil industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated as Jal Hi Power Petrochem Limited in 1990, underwent several name changes, and was most recently renamed Evexia Lifecare Limited on December 01, 2020. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 24 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: Rs 469 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 344.00<BR>- Industry P/E: 20<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.87<BR>- Return on Equity: 0.31%<BR>- Price to Book: 1.07<BR><BR>Contact Details:<BR>- Address: Village - Tundao, Tal Savli Vadodara Gujarat : 391775<BR>- Phone: 91-265-2362200/2361100<BR>- Email: kavitindustrieslimited@gmail.com<BR>- Website: http://www.evexialifecare.com

View full answer

What is the bonus history of the Evexia Lifecare?

06-Jun-2025

Evexia Lifecare issued a bonus on October 23, 2015, in a 1:3 ratio, granting one additional share for every three shares held, with the record date set for October 26, 2015.

Evexia Lifecare has a bonus history that includes a notable issue on October 23, 2015. The company announced a bonus in a ratio of 1:3, meaning that for every three shares held, shareholders received one additional share. The record date for this bonus was October 26, 2015, which is when the eligibility for receiving the bonus shares was determined. If you have any more questions about Evexia Lifecare or need further details, feel free to ask!

View full answer

Has Evexia Lifecare declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Evexia Lifecare?

03-Jun-2025

Evexia Lifecare's peers include Marico, Patanjali Foods, AWL Agri Business, Gokul Agro, and others. While Marico shows excellent management risk and capital structure, Evexia Lifecare has below-average growth and capital structure, with a 1-year return of 1.23%.

Peers: The peers of Evexia Lifecare are Marico, Patanjali Foods, AWL Agri Busine., Gokul Agro, Sundrop Brands, Gokul Refoils, Shri Venkatesh, Ajanta Soya, Vijay Solvex, and M K Proteins.<BR><BR>Quality Snapshot: Excellent management risk is observed at Marico, while Average management risk is found at Patanjali Foods, Gokul Agro, Sundrop Brands, Shri Venkatesh, Ajanta Soya, and Vijay Solvex, and the rest. Below Average management risk is seen at AWL Agri Busine., Gokul Refoils, and M K Proteins. Growth is Excellent at Patanjali Foods and Gokul Agro, Good at AWL Agri Busine. and the rest, while Below Average growth is noted at Marico, Sundrop Brands, Gokul Refoils, Evexia Lifecare, Shri Venkatesh, Ajanta Soya, Vijay Solvex, and M K Proteins. Capital Structure is Excellent at Marico and Ajanta Soya, Good at Patanjali Foods, AWL Agri Busine., Gokul Agro, and Vijay Solvex, while Below Average is observed at Gokul Refoils, Evexia Lifecare, Shri Venkatesh, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Shri Venkatesh at 93.70%, while the lowest is AWL Agri Busine. at -27.15%. Evexia Lifecare's 1-year return is 1.23%, which is significantly lower than both extremes. Additionally, Gokul Refoils, Evexia Lifecare, AWL Agri Busine., and M K Proteins have negative six-month returns.

View full answer

What is the technical trend for Evexia Lifecare?

09-Jun-2025

As of June 2, 2025, Evexia Lifecare's trend has shifted to bearish with moderate strength, supported by bearish indicators from moving averages and Bollinger Bands, despite mixed signals from the KST and MACD.

As of 2 June 2025, the technical trend for Evexia Lifecare has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating a divergence in momentum. Both the weekly and monthly Bollinger Bands are bearish, reinforcing the negative trend. Daily moving averages are also bearish, suggesting continued downward pressure. The KST shows mixed signals with a mildly bullish weekly reading and a mildly bearish monthly reading. Overall, the lack of clear signals from the RSI and Dow Theory indicates a weak trend, further supporting the bearish outlook.

View full answer

Who are the top shareholders of the Evexia Lifecare?

17-Jul-2025

The top shareholders of Evexia Lifecare include Aio Growth Capital Fund Spc at 12.17%, Raghuvir International at 1.55%, and individual investors holding 36.68%. There is minimal mutual fund and foreign institutional investor involvement, with no pledged promoter holdings.

The top shareholders of Evexia Lifecare include a mix of individual and institutional investors. The largest public shareholder is Aio Growth Capital Fund Spc, holding 12.17%. Among the promoters, Raghuvir International has the highest holding at 1.55%. Additionally, individual investors collectively hold a significant portion, accounting for 36.68% of the shares. The company also has some mutual fund involvement, with three schemes holding a total of 0.02%, and one foreign institutional investor (FII) holding 0.16%. Notably, there are no pledged promoter holdings.

View full answer

Are Evexia Lifecare latest results good or bad?

15-Aug-2025

Evexia Lifecare's latest results are concerning, with a 63.70% drop in Profit After Tax and a 5.2% decrease in net sales, leading to a 'Strong Sell' rating from MarketsMOJO. While cash reserves are at a three-year high, the overall performance is considered bad due to declining sales and profitability.

Evexia Lifecare's latest financial results indicate a challenging situation for the company. The overall performance has been flat, with a significant decline in key metrics. The Profit After Tax (PAT) for the nine-month period has dropped by 63.70% year-on-year, standing at Rs 1.06 crore. Additionally, net sales for the quarter were reported at Rs 22.09 crore, which is a decrease of 5.2% compared to the previous four quarters.<BR><BR>While there is a positive aspect in that cash and cash equivalents have reached Rs 5.27 crore, the highest level in the last three years, this does not offset the concerning trends in sales and profitability. The stock has also been rated as a 'Strong Sell' by MarketsMOJO, reflecting the financial challenges the company is currently facing. Overall, the results can be characterized as bad, given the declines in both sales and profitability.

View full answer

Is Evexia Lifecare overvalued or undervalued?

24-Oct-2025

As of October 23, 2025, Evexia Lifecare is considered overvalued with a high PE ratio of 212.41 and an EV to EBITDA ratio of 206.57, significantly contrasting with its peers, and has underperformed the market with a year-to-date decline of 42.61%.

As of 23 October 2025, Evexia Lifecare's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, based on the current financial metrics, the company remains overvalued. The PE ratio stands at an exceptionally high 212.41, while the EV to EBITDA ratio is also elevated at 206.57, suggesting that the market is pricing in significant growth expectations that may not be justified by the company's performance.<BR><BR>In comparison to its peers, Evexia Lifecare's ratios starkly contrast with those of Gulf Oil Lubricants and Veedol Corporation, which have PE ratios of 16.16 and 16.62, respectively, and EV to EBITDA ratios of 10.99 and 14.69. These peers are classified as very attractive, highlighting the disparity in valuation. Furthermore, Evexia's return metrics are concerning, with a year-to-date decline of 42.61%, significantly underperforming the Sensex's 8.21% gain during the same period. This underperformance reinforces the view that Evexia Lifecare is overvalued in the current market environment.

View full answer

When is the next results date for Evexia Lifecare?

12-Nov-2025

The next results date for Evexia Lifecare is 14 November 2025.

The next results date for Evexia Lifecare is scheduled for 14 November 2025.

View full answer

How has been the historical performance of Evexia Lifecare?

17-Nov-2025

Evexia Lifecare's historical performance shows significant sales growth from 56.29 Cr in Mar'24 to 110.48 Cr in Mar'25, despite previous declines. While operating profit improved, profitability metrics decreased, and total liabilities rose, indicating a mixed financial outlook.

Answer:<BR>The historical performance of Evexia Lifecare shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Evexia Lifecare's net sales increased from 56.29 Cr in Mar'24 to 110.48 Cr in Mar'25, marking a substantial growth. However, net sales had previously declined from 69.55 Cr in Mar'23 to 56.29 Cr in Mar'24. The total operating income followed a similar trend, rising to 110.48 Cr in Mar'25 from 56.29 Cr in Mar'24, after a dip in the preceding years. The total expenditure, excluding depreciation, also increased to 106.40 Cr in Mar'25 from 54.31 Cr in Mar'24, reflecting higher costs associated with the increased sales. Operating profit (PBDIT) improved to 4.22 Cr in Mar'25 from 2.85 Cr in Mar'24, indicating better operational efficiency. Profit before tax showed a slight decrease to 1.44 Cr in Mar'25 from 1.93 Cr in Mar'24, while profit after tax also declined to 0.93 Cr in Mar'25 from 1.38 Cr in Mar'24. The company's total liabilities rose to 883.00 Cr in Mar'24 from 847.50 Cr in Mar'23, with long-term borrowings remaining significant at 676.64 Cr in Mar'24. Cash flow from operating activities improved to 17.00 Cr in Mar'24, contrasting with a negative cash flow in the previous year, while cash flow from investing activities saw a substantial outflow of -17.00 Cr in Mar'24. Overall, Evexia Lifecare's financial performance reflects a recovery in sales and operational profit, despite challenges in profitability and increasing liabilities.

View full answer

Should I buy, sell or hold Evexia Lifecare?

19-Nov-2025

Why is Evexia Lifecare Ltd falling/rising?

02-Feb-2026

As of 02-Feb, Evexia Lifecare Ltd's stock price is rising to 1.62, reflecting a 2.53% increase after a trend reversal. However, it remains below key moving averages and shows a significant drop in investor participation, indicating ongoing challenges despite the short-term rise.

As of 02-Feb, Evexia Lifecare Ltd's stock price is rising, currently at 1.62, reflecting a change of 0.04 or 2.53% increase. This upward movement comes after a trend reversal, as the stock has gained following three consecutive days of decline. Additionally, it has outperformed its sector by 1.74% today. However, despite this rise, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a longer-term downward trend. Furthermore, there has been a significant drop in investor participation, with delivery volume on February 1st falling by 65.31% compared to the 5-day average. Overall, while the stock is experiencing a short-term rise, the broader context suggests ongoing challenges.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Weak Long Term Fundamental Strength with a -1.85% CAGR growth in Net Sales over the last 5 years

  • Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times
  • The company has been able to generate a Return on Equity (avg) of 0.88% signifying low profitability per unit of shareholders funds
2

Negative results in Sep 25

3

With ROCE of 0.1, it has a Expensive valuation with a 0.9 Enterprise value to Capital Employed

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Edible Oil

stock-summary
Market cap

INR 304 Cr (Micro Cap)

stock-summary
P/E

214.00

stock-summary
Industry P/E

15

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

2.24

stock-summary
Return on Equity

0.26%

stock-summary
Price to Book

0.56

Revenue and Profits:
Net Sales:
26 Cr
(Quarterly Results - Sep 2025)
Net Profit:
0 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.94%
0%
-8.94%
6 Months
-29.44%
0%
-29.44%
1 Year
-48.25%
0%
-48.25%
2 Years
-44.93%
0%
-44.93%
3 Years
24.43%
0%
24.43%
4 Years
-64.18%
0%
-64.18%
5 Years
-88.13%
0%
-88.13%

Evexia Lifecare for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Announcements stock-summary

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

10-Jan-2026 | Source : BSE

Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018 for the quarter ended December 31 2025

Closure of Trading Window

27-Dec-2025 | Source : BSE

Intimation of Closure of Trading Window

Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015.

19-Nov-2025 | Source : BSE

Please refer the enclosed file.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

Evexia Lifecare Ltd has announced 1:2 stock split, ex-date: 24 May 22

stock-summary
BONUS

Evexia Lifecare Ltd has announced 1:3 bonus issue, ex-date: 23 Oct 15

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-1.85%
EBIT Growth (5y)
19.82%
EBIT to Interest (avg)
-12.92
Debt to EBITDA (avg)
108.12
Net Debt to Equity (avg)
2.24
Sales to Capital Employed (avg)
0.47
Tax Ratio
27.41%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.57%
ROCE (avg)
-16.06%
ROE (avg)
0.88%

Valuation key factors

Factor
Value
P/E Ratio
214
Industry P/E
15
Price to Book Value
0.56
EV to EBIT
825.28
EV to EBITDA
573.98
EV to Capital Employed
0.86
EV to Sales
16.39
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.10%
ROE (Latest)
0.26%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 3 Schemes (0.02%)

FIIs

Held by 1 FIIs (0.47%)

Promoter with highest holding

Raghuvir International (1.55%)

Highest Public shareholder

Wave Capital Ltd (12.17%)

Individual Investors Holdings

37.36%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 16.48% vs -6.44% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -41.27% vs 103.23% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25.73",
          "val2": "22.09",
          "chgp": "16.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.11",
          "val2": "1.07",
          "chgp": "-89.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.01",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.37",
          "val2": "0.63",
          "chgp": "-41.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.43%",
          "val2": "4.84%",
          "chgp": "-4.41%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 1.72% vs 90.56% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -36.88% vs 211.89% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "47.82",
          "val2": "47.01",
          "chgp": "1.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.18",
          "val2": "1.81",
          "chgp": "-34.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.01",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.01",
          "val2": "1.60",
          "chgp": "-36.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "2.47%",
          "val2": "3.85%",
          "chgp": "-1.38%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 118.68% vs -29.83% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 216.22% vs -208.82% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "68.71",
          "val2": "31.42",
          "chgp": "118.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.98",
          "val2": "-1.16",
          "chgp": "270.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.72",
          "val2": "-1.48",
          "chgp": "216.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "2.88%",
          "val2": "-3.69%",
          "chgp": "6.57%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 96.27% vs -19.07% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -32.61% vs 105.97% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "110.48",
          "val2": "56.29",
          "chgp": "96.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.08",
          "val2": "1.98",
          "chgp": "106.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.09",
          "val2": "0.49",
          "chgp": "122.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.93",
          "val2": "1.38",
          "chgp": "-32.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "3.69%",
          "val2": "3.52%",
          "chgp": "0.17%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
25.73
22.09
16.48%
Operating Profit (PBDIT) excl Other Income
0.11
1.07
-89.72%
Interest
0.00
0.01
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.37
0.63
-41.27%
Operating Profit Margin (Excl OI)
0.43%
4.84%
-4.41%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 16.48% vs -6.44% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is -41.27% vs 103.23% in Jun 2025

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
47.82
47.01
1.72%
Operating Profit (PBDIT) excl Other Income
1.18
1.81
-34.81%
Interest
0.01
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
1.01
1.60
-36.88%
Operating Profit Margin (Excl OI)
2.47%
3.85%
-1.38%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 1.72% vs 90.56% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is -36.88% vs 211.89% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
68.71
31.42
118.68%
Operating Profit (PBDIT) excl Other Income
1.98
-1.16
270.69%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
1.72
-1.48
216.22%
Operating Profit Margin (Excl OI)
2.88%
-3.69%
6.57%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 118.68% vs -29.83% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2024 is 216.22% vs -208.82% in Dec 2023

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
110.48
56.29
96.27%
Operating Profit (PBDIT) excl Other Income
4.08
1.98
106.06%
Interest
1.09
0.49
122.45%
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.93
1.38
-32.61%
Operating Profit Margin (Excl OI)
3.69%
3.52%
0.17%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 96.27% vs -19.07% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -32.61% vs 105.97% in Mar 2024

stock-summaryCompany CV
About Evexia Lifecare Ltd stock-summary
stock-summary
Evexia Lifecare Ltd
Micro Cap
Edible Oil
Evexia Lifecare Limited was originally incorporated with the name Jal Hi Power Petrochem Limited on November 11, 1990, which later on changed to Atreya Petrochem Limited on 21 September 2000. In 2016, the Company again changed its name from Atreya Petrochem Limited to Kavit Industries Limited on December 27, 2010. Subsequently, the name of the Company was changed from Kavit Industries Limited to Evexia Lifecare Limited on December 01, 2020.
Company Coordinates stock-summary
Company Details
Village - Tundao, Tal Savli Vadodara Gujarat : 391775
stock-summary
Tel: 91-265-2362200/2361100
stock-summary
kavitindustrieslimited@gmail.com
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai